INJ
Injective (INJ) Bull Case: Upgrade Approval, ~2M Accumulation, and $3.50–$4.00 Targets
Injective’s recent governance-approved upgrade and roughly 2 million INJ of on-chain accumulation create a favorable setup. This case study reconciles the upgrade mechanics, accumulation dynamics, analyst technicals, and risk-adjusted trade scenarios for speculative allocators.
Published at 2026-02-21 15:50:47